bs-2489R

- DATASHEET -

[Primary Antibody]

CD9 Rabbit pAb

Bio'ss ANTIBODIES

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

Applications: WB (1:500-2000) Flow-Cyt (1µg/Test)

Reactivity: Human, Mouse, Rat (predicted: Rabbit, Pig, Sheep, Cow, Dog)

Predicted MW.: ^{24 kDa}

Subcellular Location: Cell membrane

Host: Rabbit	
Clonality: Polyclona	l

SWISS: P21926

Isotype: IgG

GenelD: 928 Target: CD9

Immunogen: KLH conjugated synthetic peptide derived from human CD9: 101-200/228. < Extracellular >

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: This gene encodes a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Tetraspanins are cell surface glycoproteins with four transmembrane domains that form multimeric complexes with other cell surface proteins. The encoded protein functions in many cellular processes including differentiation, adhesion, and signal transduction, and expression of this gene plays a critical role in the suppression of cancer cell motility and metastasis. [provided by RefSeq, Jan 2011]

– VALIDATION IMAGES -



Sample: Lane 1: Testis (Mouse) Lysate at 40 ug Lane 2: Placenta (Mouse) Lysate at 40 ug Lane 3: Testis (Rat) Lysate at 40 ug Primary: Anti-CD9 (bs-2489R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 24 kD Observed band size: 24 kD



Blank control: Mouse spleen cells(blue). Primary Antibody:Rabbit Anti-CD9 antibody(bs-2489R), Dilution: 1µg in 100 µL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA. Protocol Primary antibody were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific proteinprotein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.



Blank control: RSC96 cells (blue), Primary Antibody:Rabbit Anti-CD9 antibody(bs-2489R), Dilution: 1µg in 100 µL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA. Protocol Primary antibody were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 10% goat serum (15 min) to block non-specific proteinprotein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.

- SELECTED CITATIONS -

- [IF=18] Zetao Wang. et al. Nano-vibration exciter: Hypoxia-inducible factor 1 signaling pathway-mediated extracellular vesicles as bioactive glass substitutes for bone regeneration. BIOACT MATER. 2024 Oct;40:460 WB ;MOUSE. 10.1016/j.bioactmat.2024.06.023
- [IF=15.5] Yuan Liu. et al. Mesenchymal stromal/stem cell tissue source and in vitro expansion impact extracellular

vesicle protein and miRNA compositions as well as angiogenic and immunomodulatory capacities. J EXTRACELL VESICLES. 2024 Aug;13(8):e12472 WB ;Rat. 39092563

- [IF=14.976] Qinyu Ma. et al. Small extracellular vesicles deliver osteolytic effectors and mediate cancer induced osteolysis in bone metastatic niche. J Extracell Vesicles. 2021 Feb;10(4):e12068 WB ;MOUSE. 33659051
- [IF=10.9] Zetao Wang. et al. Extracellular vesicles loaded dual-network bioactive sealant via immunoregulation and annulus fibrosus repair for intervertebral disc herniation. J MATER SCI TECHNOL. 2024 Jun;184:75 WB ;Human. 10.1016/j.jmst.2023.10.034
- [IF=10] Yi He. et al. Elimination of Senescent Osteocytes by Bone-Targeting Delivery of β-Galactose-Modified Maytansinoid Prevents Age-Related Bone Loss. ADV HEALTHC MATER. 2023 Dec;:2302972 WB ;MOUSE. 38063283